山东金城医药股份有限公司 2016 年第三季度报告全文 山东金城医药股份有限公司 2016 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 山东金城医药股份有限公司 所有董事均已出席了审议本次季报的董事会会议。 2016 年第三季度报告 公司负责人赵叶青、主管会计工作负责人崔希礼及会计机构负责人(会计主 管人员)孙瑞梅声明：保证季度报告中财务报告的真实、完整。 2016 年 10 月 2 1 山东金城医药股份有限公司 2016 年第三季度报告全文 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,097,549,822.24 | 1,996,292,206.98 | | 5.07% | | 归属于上市公司股东的净资产 | 1,37 ...

山东金城医药股份有限公司 2016 年半年度报告全文 山东金城医药股份有限公司 2016 年半年度报告 2016 年 07 月 1 山东金城医药股份有限公司 2016 年半年度报告全文 第一节 重要提示、释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性、完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事会会议。 公司负责人赵叶青、主管会计工作负责人崔希礼及会计机构负责人(会计主 管人员)孙瑞梅声明：保证年度报告中财务报告的真实、准确、完整。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司半年度财务报告已经大信会计师事务所（特殊普通合伙）审计并被出 具标准审计报告。 2 | 目录 | | --- | | 第一节 | 重要提示、释义 2 | | --- | --- | | 第二节 | 公司基本情况简介 5 | | 第三节 | 董事会报告 9 | | 第四节 | 重要事项 25 | | 第五节 | 股份变动及股东情况 37 | | 第六节 | 董事、监事、高级管理人员情况 42 | | 第七节 ...

山东金城医药股份有限公司 2016 年第一季度报告全文 山东金城医药股份有限公司 2016 年第一季度报告 2016 年 04 月 1 山东金城医药股份有限公司 2016 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人崔希礼及会计机构负责人(会计主 管人员)孙瑞梅声明：保证季度报告中财务报告的真实、完整。 2 山东金城医药股份有限公司 2016 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期 | | --- | --- | --- | --- | | | | | 增减 | | 营业总收入（元） | 253,623,312.40 | 275,858,292.97 | -8.06% | | 归属于上市公司股东的净 ...

山东金城医药化工股份有限公司 2015 年年度报告全文 山东金城医药化工股份有限公司 2015 年年度报告 2016 年 02 月 1 山东金城医药化工股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人赵叶青、主管会计工作负责人崔希礼及会计机构负责人(会计主 管人员)孙瑞梅声明：保证年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议。 | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 赵鸿富 | 董事 | 出差未归 | 赵叶青 | | 倪浩嫣 | 独立董事 | 工作原因 | 赵耀 | 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 2015 年是医药政策年，国家发改委、国务院、CFDA 等部门相继出台了多项 医药改革政策，主要包括：基本医疗保 ...

山东金城医药化工股份有限公司 2015 年第三季度报告全文 山东金城医药化工股份有限公司 2015 年第三季度报告 2015 年 10 月 1 山东金城医药化工股份有限公司 2015 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人崔希礼及会计机构负责人(会计主管人员)孙瑞 梅声明：保证季度报告中财务报告的真实、完整。 2 山东金城医药化工股份有限公司 2015 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | 本报告期末比上年度末 | | | --- | --- | --- | --- | --- | | | | | 增减 | | | 总资产（元） | 1,878,083,576.64 | | 1,785,278,864.30 ...

山东金城医药化工股份有限公司 2015 年半年度报告全文 山东金城医药化工股份有限公司 2015 年半年度报告 2015 年 08 月 1 山东金城医药化工股份有限公司 2015 年半年度报告全文 第一节 重要提示、释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性、完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事会会议。 公司负责人赵叶青、主管会计工作负责人崔希礼及会计机构负责人(会计主 管人员)孙瑞梅声明：保证本半年度报告中财务报告的真实、完整。 公司经本次董事会审议通过的利润分配预案为：以目前公司总股本 126,600,000 股为基数，向全体股东每 10 股派发现金红利 0.00 元（含税），送红 股 0 股（含税），以资本公积金向全体股东每 10 股转增 10 股。 公司半年度财务报告已经大信会计师事务所（特殊普通合伙）审计并被出 具标准审计报告。 2 | | | 山东金城医药化工股份有限公司 2015 年半年度报告全文 释义 | | 释义项 | 指 | 释义内容 | | --- | --- ...

Financial Performance - Total revenue for Q1 2015 was CNY 275,858,292.97, representing a 16.98% increase compared to CNY 235,819,918.91 in the same period last year[9]. - Net profit attributable to ordinary shareholders was CNY 38,492,254.56, a significant increase of 89.37% from CNY 20,326,980.26 year-on-year[9]. - Basic earnings per share rose to CNY 0.30, a 76.47% increase compared to CNY 0.17 in the same period last year[9]. - Operating profit reached CNY 43,132,559.79, representing a year-on-year growth of 71.19%[29]. - Total profit amounted to CNY 45,375,966.52, up 72.5% compared to the previous year[29]. - The company achieved investment income of CNY 3,500,000.00 in Q1 2015, contributing positively to the overall profit[69]. - The total profit for Q1 2015 was CNY 45,375,966.52, compared to CNY 26,305,376.97 in Q1 2014, showing a growth of approximately 72.5%[65]. - The net profit for Q1 2015 reached CNY 38,492,254.56, compared to CNY 20,326,980.26 in Q1 2014, indicating a year-over-year increase of about 89.5%[66]. Cash Flow and Financial Position - Net cash flow from operating activities reached CNY 52,510,505.72, up by 13.90% from CNY 46,103,952.97 in the previous year[9]. - Cash flow from operating activities showed a net outflow of CNY 17,751,535.21, an improvement from a net outflow of CNY 20,245,833.80 in the previous period[74]. - The ending balance of cash and cash equivalents was CNY 375,334,488.09, compared to CNY 309,363,109.64 at the end of the previous period, representing an increase of 21.3%[74]. - Cash and cash equivalents at the end of Q1 2015 were CNY 216,663,048.51, slightly up from CNY 210,417,894.99[60]. - The company reported cash dividends of CNY 37.89 million, distributing CNY 3 per 10 shares to shareholders[51]. Shareholder Information - The total number of shareholders at the end of the reporting period is 7,684[18]. - The largest shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 37.67% of shares, totaling 47,580,000 shares[18]. - Zhao Hongfu and Zhao Yeqing together control 57.64% of the shares through their holdings in the largest shareholder[19]. - The total number of unrestricted shares held by the top 10 shareholders is 66,000,000 shares[18]. - The company has a total of 4,791,000 shares under lock-up for Zhao Hongfu, which are subject to high-level management restrictions[21]. Strategic Initiatives and Market Position - The company is actively pursuing strategic transformation and investment mergers to enhance competitiveness and mitigate risks associated with market changes[13]. - The company plans to accelerate the development of new products and technologies to enhance market position and address competitive pressures[12]. - The company is focusing on enhancing its market position through strategic stock incentives, which may lead to improved performance in the upcoming quarters[22][23]. - The company is investing in new product development and technology innovation to mitigate risks associated with long R&D cycles and market changes[38]. - The company is pursuing capital operations to accelerate the development of its pharmaceutical divisions and is undergoing significant asset restructuring to enhance its industry chain integration[34]. Risks and Challenges - The company is facing intensified competition in the antibiotic industry due to stricter regulations and market dynamics, which may impact product pricing and profit margins[12]. - The company emphasizes environmental protection and compliance with new regulations, which may pose operational risks if not adhered to[15]. - The company faces management risks due to its expanding scale and is committed to enhancing its management capabilities to ensure stable growth[36]. - The company is addressing safety and environmental pressures by improving its safety management systems and complying with stricter environmental regulations[37]. Investment and Projects - The company has initiated a project for a 200 tons/year glutathione raw material production facility, which has started to yield benefits, although there are risks related to market competition and expected returns[13]. - The company plans to invest CNY 64.79 million from previously committed funds into a 200 tons/year glutathione raw material project, with a total investment of CNY 201.20 million[48]. - The company has not yet initiated the 500 tons/year furan ammonium salt industrialization project as the implementation timing is not mature[47]. - The company is in the process of a major asset restructuring, aiming to acquire a sizable formulation enterprise[50]. Compliance and Governance - The company reported a commitment from its controlling shareholder, Jincheng Industrial, to not transfer or manage shares for 36 months post-IPO[42]. - The company ensures that any related party transactions will be conducted on a fair and open market basis[43]. - The company has not engaged in any activities that would harm the interests of Jincheng Pharmaceutical or its minority shareholders[43]. - The company is committed to maintaining compliance with its promises regarding share transfers and related party transactions[43].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2014, representing a year-on-year increase of 15%[17]. - Net profit attributable to shareholders reached RMB 150 million, an increase of 10% compared to the previous year[17]. - The gross profit margin improved to 35%, up from 32% in 2013, indicating better cost management and pricing strategies[17]. - The company's operating revenue for 2014 was ¥1,050,829,973.76, representing a 15.64% increase compared to ¥908,713,118.01 in 2013[18]. - The net profit attributable to shareholders was ¥108,700,716.78, a significant increase of 68.28% from ¥64,596,722.57 in the previous year[18]. - The net cash flow from operating activities reached ¥219,455,483.56, marking a 133.66% increase from ¥93,921,980.24 in 2013[18]. - The company's total assets at the end of 2014 were ¥1,785,278,864.30, up 13.29% from ¥1,575,802,813.68 in 2013[18]. - The total liabilities increased by 20.66% to ¥668,605,864.17 from ¥554,108,595.31 in the previous year[18]. - The weighted average return on equity rose to 10.16%, an increase of 3.69% compared to 6.47% in 2013[18]. - The company reported a basic earnings per share of ¥0.88, which is a 66.04% increase from ¥0.53 in the previous year[18]. Market Expansion and Product Development - User data showed a growth in customer base by 20%, with active users reaching 500,000 by the end of 2014[17]. - The company plans to launch three new pharmaceutical products in 2015, targeting a market share increase of 5% in the next fiscal year[17]. - The company is exploring market expansion opportunities in Southeast Asia, aiming for a 10% revenue contribution from this region by 2016[17]. - The company is focusing on expanding its product lines in biopharmaceuticals and health products, with several projects in various stages of development, including Imatinib and Adenosylmethionine[46][45]. - The company plans to continue developing high-end pharmaceutical intermediates and has ongoing projects for various chemical drugs and biopharmaceuticals[45]. Research and Development - Research and development expenses accounted for 8% of total revenue, reflecting the company's commitment to innovation and new technology[17]. - The company's R&D investment amounted to CNY 49.68 million, accounting for 4.73% of total revenue, a decrease from 5.59% in 2013[46]. - The company introduced 2 PhD and 12 master's degree holders during the reporting period, enhancing its talent pool[51]. - The company has established a comprehensive new product and process development system, contributing to its growth and market expansion[76]. Strategic Acquisitions and Investments - A strategic acquisition of a local competitor is under consideration to enhance market presence and operational efficiency[17]. - The company acquired Shanghai Tianchen Pharmaceutical Co., enhancing its pharmaceutical industrial chain[34]. - The company plans to acquire 100% equity of Tianchen Pharmaceutical for CNY 50.30 million, enhancing its strategic positioning in the industry[105][106]. - The company invested a total of ¥50,300,000 in external investments during the reporting period, representing a significant increase of 1,047.92% compared to ¥4,800,000 in the previous year[62]. Compliance and Risk Management - The company emphasizes the importance of compliance with GMP standards, ensuring product quality and safety in its operations[17]. - The company faces risks from intensified industry competition and regulatory changes affecting antibiotic usage, which may impact profit margins[26]. - The company is actively pursuing strategic transformation and investment opportunities, which may involve risks related to market conditions and management capabilities[26]. - Environmental protection regulations are becoming stricter, and failure to comply may result in penalties or operational disruptions for the company[28]. - The company is exposed to risks related to product quality and safety, which could significantly impact its operations and reputation[87]. Shareholder and Governance Structure - The company has established a strict insider information management system to ensure compliance with regulations and protect shareholder interests[96][97]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing, with a maximum of 25% of shares allowed for transfer annually thereafter[132]. - The total number of shareholders at the end of the reporting period was 7,684[157]. - The company has a total of 539.89 million shares held by directors and senior management, with stock options granted but not exercised during the reporting period[182]. - The company has independent directors with significant experience in finance and law, enhancing governance and oversight[178]. Operational Efficiency and Management - The company aims to improve operational efficiency and reduce costs in the next fiscal year[169]. - The company will strengthen production management and quality control to improve operational efficiency and adapt to its expanding business scale[86]. - The management team has undergone changes, with several key personnel transitioning in and out of their roles[170]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with laws and regulations[189]. Financial Management and Dividend Policy - In 2014, the company achieved a net profit of CNY 49,408,072.58, with a cash dividend distribution of CNY 37,892,400, representing 34.86% of the net profit attributable to shareholders[93][95]. - The cash dividend per 10 shares for 2014 was CNY 3.00, with a total of 12,630,800 shares as the base for distribution[93]. - The company maintained a consistent cash dividend policy over the past three years, with increasing amounts distributed each year[95]. - The company reported a cumulative undistributed profit of CNY 176,625,332.53 at the end of 2014, which includes profits from previous years[93].

Financial Performance - Total revenue for the reporting period reached CNY 258,275,724.93, representing a 23.25% increase year-on-year[8] - Net profit attributable to shareholders increased by 81.61% to CNY 22,757,051.81 for the reporting period[8] - Basic earnings per share rose by 80.00% to CNY 0.18[8] - The weighted average return on equity increased by 69.05% to 2.13% for the reporting period[8] - The company achieved a total operating revenue of ¥757.80 million, representing a year-on-year growth of 17.74%, with a net profit attributable to shareholders of ¥76.20 million, up 85.78%[32] - The total comprehensive income for the period was CNY 76,198,614.52, compared to CNY 41,015,513.31 in the previous year, marking a significant increase[78] Assets and Liabilities - Total assets increased by 6.18% to CNY 1,673,232,412.60 compared to the end of the previous year[8] - The company's total liabilities were reported at CNY 593,960,332.01, compared to CNY 554,108,595.31 at the beginning of the period[68] - The company's total equity increased to CNY 1,079,272,080.59 from CNY 1,021,694,218.37 at the beginning of the period[68] - Accounts receivable decreased by 56.39% to ¥26,558,421.26 compared to the beginning of the year, primarily due to an increase in receivables from purchased goods and services[27] - Other receivables decreased by 49.32% to ¥1,512,527.80, primarily due to the receipt of export tax refunds[27] Shareholder Information - The total number of shareholders at the end of the reporting period is 7,091[16] - The largest shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 37.67% of the shares, totaling 47,580,000 shares[16] - Zhao Hongfu, a natural person shareholder, holds 5.45% of the shares, amounting to 6,888,000 shares, with 5,166,000 shares under lock-up[16] - The report indicates that there are no agreed repurchase transactions conducted by shareholders during the reporting period[17] Management and Strategy - The company is focusing on strategic transformation towards a "big pharmaceutical, big health" industry positioning[11] - The company plans to enhance internal management processes and strengthen human resources to support strategic transformation[12] - The company is focusing on enhancing its management level through the implementation of a group management system and information technology upgrades[37] - The company is committed to advancing product research and technological innovation while optimizing internal management processes[41] Investment and Projects - The company has completed the construction of a multifunctional comprehensive workshop, which is expected to accelerate new product industrialization[13] - The company plans to accelerate product R&D to optimize its product structure and enhance core competitiveness through technological innovation[36] - The acquisition of 100% equity in Shanghai Tianchen Pharmaceutical Co., Ltd. is expected to enhance the company's strategic transformation and expand its product offerings[37] - The total amount of raised funds is CNY 52,806.8 million, with CNY 922.27 million invested in the current quarter[53] Risks and Challenges - The company is facing risks related to the implementation of fundraising projects, particularly in achieving expected returns[12] - The company faces significant management and operational risks due to its strategic transformation and expansion, requiring higher management, technical innovation, and marketing capabilities[41] - The company has a large amount of accounts receivable, which poses a risk to its performance and operations if not collected on time[42] Environmental and Social Responsibility - The company has increased its investment in environmental protection and strengthened the construction of environmental protection infrastructure during the reporting period[38] - The company actively participates in social welfare activities, including supporting underprivileged students through charity initiatives[39] - The company is focusing on pollution control and the application of new technologies and equipment for environmental protection[41] Stock Incentive Plan - The company unlocked a total of 1,200,000 restricted stocks as part of the equity incentive plan[20] - Key executives received significant stock allocations, with the highest being 90,000 shares for Yang Xiuliang[20] - The stock incentive plan reflects the company's strategy to align management interests with shareholder value[20] - The distribution of shares among executives shows a structured approach to performance rewards[20]

Financial Performance - Total operating revenue for the first half of 2014 was CNY 499,525,796.80, an increase of 15.09% compared to CNY 434,047,633.76 in the same period last year[18]. - Net profit attributable to shareholders of the listed company reached CNY 53,441,562.71, representing an increase of 87.62% from CNY 28,484,649.36 year-on-year[18]. - Net cash flow from operating activities was CNY 88,844,245.88, a significant increase of 223.12% compared to CNY 27,495,595.01 in the previous year[18]. - Basic earnings per share rose to CNY 0.44, an increase of 83.33% from CNY 0.24 in the same period last year[18]. - The net profit after deducting non-recurring gains and losses was CNY 52,537,661.82, an increase of 71.78% from CNY 30,584,344.52 in the previous year[18]. - The company reported a total equity attributable to shareholders of CNY 1,115,873,386.86, which is a 9.22% increase from CNY 1,021,694,218.37 at the end of the previous year[18]. - Operating profit amounted to CNY 63,293,040.50, up 67.5% from CNY 37,780,600.57 in the previous year[144]. - The diluted earnings per share for 2013 was calculated at CNY 0.51 after the issuance of new shares[121]. Revenue Growth - The company reported a 62.87% increase in sales revenue for its biopharmaceutical and specialty raw materials series, totaling CNY 87.49 million[38]. - The sales revenue from the biopharmaceutical sector's glutathione products saw substantial growth compared to the same period last year[33]. - The company’s export sales revenue reached CNY 242 million, marking a 54% year-on-year increase[39]. - Revenue from the cephalosporin side chain active ester series products reached ¥218,460,796.77, with a year-on-year increase of 5.94%[41]. - The revenue from the biopharmaceutical segment increased by 62.87% year-on-year, while the cost of goods sold rose by 51.65%[41]. Research and Development - R&D investment increased by 13.08% to CNY 24.29 million, reflecting the company's commitment to innovation[35]. - The company holds a total of 23 patents, with 2 new invention patents granted during the reporting period[47]. - The company has completed small-scale research for 13 key products, with several projects moving towards pilot testing and quality research[48]. - The company aims to enhance its core competitiveness through the transformation of patented technologies and ongoing product development projects[48]. Strategic Focus - The company is focusing on strategic upgrades and transformation to enhance its pharmaceutical industrial chain[33]. - The company is actively monitoring industry policy changes to adapt its operations and ensure stable growth[28]. - The biopharmaceutical sector is identified as a key development area, with the government implementing policies to support rapid growth and innovation in the industry[52]. - The company is focusing on expanding its product structure and upgrading its capabilities in response to the evolving pharmaceutical industry landscape[49]. Financial Management - The company has implemented a credit assessment system for customers to mitigate the risk of accounts receivable, which remains significant[62]. - The company plans to address risks related to export tax rebates and exchange rate fluctuations by adjusting pricing strategies and contract terms[63]. - The company has committed to investing 20,120 million CNY in the 200 tons/year glutathione raw material project, with 6,479.31 million CNY redirected from previous commitments[66]. - The company has achieved a 96.87% progress rate on the 3,000 tons/year AE-active ester project, with total investment of 7,900.96 million CNY[67]. Corporate Governance - The company appointed new independent directors on April 3, 2014, as part of its governance changes[131]. - The company has a long-term commitment to avoid any related party transactions that could harm the interests of the company and its minority shareholders[113]. - The company’s board members and senior management have pledged to report their shareholdings and any changes annually, with a maximum transfer limit of 25% of their total shareholdings[113]. Shareholder Information - The number of shareholders reached 7,759 by the end of the reporting period[123]. - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. reduced its holdings by 5,256,157 shares, holding 5,918,800 shares, accounting for 4.69% of total shares[123]. - The company’s major shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 37.72% of the shares, with 23.5 million shares pledged[123]. Environmental and Social Responsibility - The company has been recognized with multiple awards for its safety and environmental practices, reflecting its commitment to sustainable development[58]. - The company is focusing on enhancing its management system and risk control capabilities, leading to improved operational efficiency and compliance with regulations[56]. - The company has invested in environmental protection and infrastructure, implementing projects to enhance production efficiency and reduce costs[53]. Cash Flow and Investments - Cash flow from operating activities was CNY 583,682,884.88, compared to CNY 467,429,032.63 in the same period last year[149]. - The net cash flow from investing activities was negative at CNY -58,430,898.65, compared to CNY -73,849,265.52 in the same period last year, showing an improvement of about 21%[151]. - Cash inflow from financing activities totaled CNY 106,936,800.00, a significant increase from CNY 44,000,000.00 in the previous year, representing a growth of approximately 143.5%[151]. Compliance and Regulations - The company did not undergo an audit for the semi-annual financial report, which may affect the reliability of the financial data presented[134]. - The company’s financial statements comply with the requirements of the "Enterprise Accounting Standards" and reflect its financial status accurately[178].